| P50 | author | Shahram Bahmanyar | Q41661459 |
| | Lena Brundin | Q77327079 |
| P2093 | author name string | Tomas Olsson | |
| | Scott Montgomery | |
| | Sarah Burkill | |
| | Ellen Iacobaeus | |
| | Michael Fored | |
| | Ramil Hakim | |
| | Camilla Byström | |
| P2860 | cites work | Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps | Q26823444 |
| | Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. | Q30249052 |
| | Progressive multifocal leukoencephalopathy. | Q30365798 |
| | Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. | Q30583907 |
| | PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 |
| | Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases | Q30815289 |
| | Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data | Q33446236 |
| | Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis | Q34089586 |
| | Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease | Q34538727 |
| | Determinants of survival in progressive multifocal leukoencephalopathy | Q35012056 |
| | Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy | Q36234255 |
| | Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies | Q37331090 |
| | Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study | Q37434587 |
| | Patient Registries: Utility, Validity and Inference | Q37786241 |
| | Update on progressive multifocal leukoencephalopathy | Q38044681 |
| | The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases | Q38190094 |
| | A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy | Q38268951 |
| | Changing incidence of central nervous system diseases in the EuroSIDA cohort | Q38479888 |
| | Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy? | Q38752797 |
| | Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system | Q39705818 |
| | Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML. | Q40836041 |
| | Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases | Q44893878 |
| | Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis | Q46406633 |
| | Nested PCR for detection of BK virus and JC virus DNA. | Q48141855 |
| | Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study | Q48828618 |
| | Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient. | Q53517226 |
| | Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies | Q60962707 |
| | [Better treatment has reduced AIDS mortality. Increased number of patients with HIV infections will burden the ambulatory care services] | Q74595016 |
| | Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population | Q80243718 |
| | Increase of reported HIV infections in Sweden | Q81295929 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Sweden | Q34 |
| P304 | page(s) | e498-e506 | |
| P577 | publication date | 2018-01-10 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | The national incidence of PML in Sweden, 1988-2013 | |
| P478 | volume | 90 | |